MX2017005883A - Administracion oral de farmacos inestables o deficientemente absorbidos. - Google Patents

Administracion oral de farmacos inestables o deficientemente absorbidos.

Info

Publication number
MX2017005883A
MX2017005883A MX2017005883A MX2017005883A MX2017005883A MX 2017005883 A MX2017005883 A MX 2017005883A MX 2017005883 A MX2017005883 A MX 2017005883A MX 2017005883 A MX2017005883 A MX 2017005883A MX 2017005883 A MX2017005883 A MX 2017005883A
Authority
MX
Mexico
Prior art keywords
dosage forms
oral administration
drug
poorly
unstable
Prior art date
Application number
MX2017005883A
Other languages
English (en)
Inventor
YANG Yu-tsai
Wang Jong-Jing
HSU Pei-jing
Chang Li-Chien
Hao Wei-Hua
Hsu Chang-Shan
Original Assignee
Innopharmax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innopharmax Inc filed Critical Innopharmax Inc
Publication of MX2017005883A publication Critical patent/MX2017005883A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La descripción se relaciona a una forma de dosificación y combinaciones de formas de dosificación útiles para administración oral eficaz de fármacos que de otro modo no son adecuados para administración oral, degradación debido al ácido y/o mediada por proteasa. Las formas de dosificación incluyen un sistema de administración de fármaco auto-micro emulsionante (SMEDDS) al cual se combina el fármaco y un antiácido. Cuando se co-administra al mamífero, las formas de dosificación pueden prevenir degradación del fármaco mediante el ácido fuerte y enzimas digestivas normalmente presentes en un entorno gástrico, y pueden mejorar la absorción de fármacos soluble en agua en el tracto gastrointestinal (GI). Las formas de dosificación se pueden usar para administrar de manera eficaz insulina por una vía oral, por ejemplo, tal como en la forma de un polvo que se puede almacenar durante largos periodos y reconstituirse con agua u otro fluido poco antes de la administración.
MX2017005883A 2014-11-04 2015-11-04 Administracion oral de farmacos inestables o deficientemente absorbidos. MX2017005883A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462075144P 2014-11-04 2014-11-04
US201562197286P 2015-07-27 2015-07-27
PCT/IB2015/002181 WO2016071756A1 (en) 2014-11-04 2015-11-04 Oral administration of unstable or poorly-absorbed drugs

Publications (1)

Publication Number Publication Date
MX2017005883A true MX2017005883A (es) 2017-11-28

Family

ID=55908656

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005883A MX2017005883A (es) 2014-11-04 2015-11-04 Administracion oral de farmacos inestables o deficientemente absorbidos.

Country Status (15)

Country Link
US (2) US11331376B2 (es)
EP (1) EP3215128B1 (es)
JP (1) JP6797115B2 (es)
KR (1) KR102502308B1 (es)
CN (1) CN107205928B (es)
AU (1) AU2015341479B2 (es)
CA (1) CA2966619C (es)
ES (1) ES2759004T3 (es)
IL (1) IL252080B (es)
MX (1) MX2017005883A (es)
MY (1) MY194945A (es)
RU (1) RU2746548C2 (es)
SG (1) SG11201703593PA (es)
TW (1) TWI728959B (es)
WO (1) WO2016071756A1 (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591680A (en) * 1969-11-17 1971-07-06 Smith Kline French Lab Concentrated antacid compositions and method of producing antacid activity
US4327076A (en) 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
CA2316539C (en) 1997-12-26 2008-11-18 Yamanouchi Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6656701B2 (en) 1999-07-16 2003-12-02 Actim Organics, Inc Combination of acid protease enzymes and acidic buffers and uses thereof
CN1160122C (zh) * 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
SK15172003A3 (en) 2001-06-21 2004-11-03 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
US20040142040A1 (en) * 2002-10-31 2004-07-22 Dong Liang C. Formulation and dosage form providing increased bioavailability of hydrophobic drugs
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
MY151470A (en) * 2005-12-28 2014-05-30 Takeda Pharmaceutical Controlled release solid preparation
SG184754A1 (en) * 2005-12-28 2012-10-30 Takeda Pharmaceutical Controlled release solid preparation
ES2572157T3 (es) 2007-09-03 2016-05-30 Nanotherapeutics Inc Composiciones en forma de partículas para la administración de fármacos poco solubles
US20090130198A1 (en) * 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
FR2925333B1 (fr) 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
CN102227213A (zh) 2008-11-28 2011-10-26 诺沃—诺迪斯克有限公司 适合于衍生化的胰岛素肽的口服施用的药物组合物
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
EP2523655A2 (en) * 2010-01-12 2012-11-21 Novo Nordisk A/S Pharmaceutical compositions for oral administration of insulin peptides
MX355760B (es) * 2010-12-13 2018-04-27 Salix Pharmaceuticals Inc Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas.
US20120213855A1 (en) * 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
US20140127296A1 (en) 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes

Also Published As

Publication number Publication date
US20170360894A1 (en) 2017-12-21
AU2015341479B2 (en) 2020-11-26
CA2966619C (en) 2023-03-14
TW201632172A (zh) 2016-09-16
KR102502308B1 (ko) 2023-02-21
RU2017119212A3 (es) 2019-05-24
CN107205928B (zh) 2021-05-11
ES2759004T3 (es) 2020-05-07
SG11201703593PA (en) 2017-06-29
EP3215128A4 (en) 2017-11-29
CA2966619A1 (en) 2016-05-12
MY194945A (en) 2022-12-27
US11331376B2 (en) 2022-05-17
CN107205928A (zh) 2017-09-26
WO2016071756A1 (en) 2016-05-12
IL252080B (en) 2021-03-25
IL252080A0 (en) 2017-07-31
JP2017533239A (ja) 2017-11-09
TWI728959B (zh) 2021-06-01
RU2746548C2 (ru) 2021-04-15
EP3215128A1 (en) 2017-09-13
RU2017119212A (ru) 2018-12-05
JP6797115B2 (ja) 2020-12-09
AU2015341479A1 (en) 2017-06-15
KR20170099881A (ko) 2017-09-01
EP3215128B1 (en) 2019-09-04
US20220233649A1 (en) 2022-07-28
BR112017009326A2 (pt) 2017-12-19

Similar Documents

Publication Publication Date Title
EP4233978A3 (en) Oral delivery of active drug substances
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX340822B (es) Formulaciones para suministro oral de adsorbentes en el intestino.
NZ704584A (en) Liquid stable virus vaccines
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
IN2014DN06737A (es)
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
WO2014044794A3 (en) Pharmaceutical composition
PH12014502191A1 (en) Capsule disintegrable in large-intestine-specific manner
TN2017000235A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
PL3793534T3 (pl) Tabletka doustna do dostarczania składników czynnych do przewodu żołądkowo-jelitowego
EA201591188A1 (ru) Доставка глатирамера ацетата через слизистую оболочку
MX365216B (es) Forma de dosificacion por via oral de difenhidramina de disolucion rapida.
MX2016010892A (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica.
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
MX2017005883A (es) Administracion oral de farmacos inestables o deficientemente absorbidos.
PH12014501822A1 (en) Oral formulation comprising lansoprazole and the preparation method thereof
NZ707033A (en) Dispersible nimorazole tablet
EA201790089A1 (ru) Фармацевтические средства для лечения головокружения различной этиологии
SA515360445B1 (ar) قرص قابل للتشتيت
MX2019001399A (es) Formulacion de calcitonina estable a temperatura ambiente para la via oral.
DK201270714A (en) Dispersible tablet
TH167686B (th) สารตัวยาแบบผสมผสานซึ่งประกอบรวมด้วยเฟนิเลฟรีนและพาราเซตามอล